IDH1 and IDH2 mutations (hereafter referred to as IDH mutation) are mutually exclusive “truncal mutations”, which are frequently associated with better prognoses for gliomas, such as Grade II and Grade III gliomas, and thereby considered as prognostic factors for gliomas [9,10]. This evidence concerns the gene IDH2 and central nervous system cancer.